Metastatic Solid Tumor

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

79 drugs in development·42 companies·29 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
pedmark	FENNEC PHARMACEUTICALS INC. (FENC)

Phase 3(11)

Drug	Company
AZD5305	ASTRAZENECA PLC (AZN)
Cetuximab	BeOne Medicines Ltd. (ONC)
Lazertinib	ENANTA PHARMACEUTICALS INC (ENTA)
MK-0472	Merck & Co., Inc. (MRK)
MK-1084	Merck & Co., Inc. (MRK)
Pemetrexed	ELI LILLY & Co (LLY)
surzebiclimab	BeOne Medicines Ltd. (ONC)
tak-188	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-188	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-981	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-981	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(7)

Drug	Company
Amivantamab	ENANTA PHARMACEUTICALS INC (ENTA)
azd5305 microtracer	ASTRAZENECA PLC (AZN)
BGB-53038	BeOne Medicines Ltd. (ONC)
Direct Oral Anticoagulant	Structure Therapeutics Inc. (GPCR)
iph4502	Innate Pharma S.A. (IPHA)
pc14586	PMV Pharmaceuticals, Inc. (PMVP)
Pemetrexed	Structure Therapeutics Inc. (GPCR)

Phase 1(42)

Drug	Company
amg 410	AMGEN INC (AMGN)
amg 510	AMGEN INC (AMGN)
BGB-53038	ENANTA PHARMACEUTICALS INC (ENTA)
BGB-B455	Merus N.V. (MRUS)
CB-708 (ATG-037)	Calithera Biosciences, Inc. (CALA)
chs-114	Coherus Oncology, Inc. (CHRS)
CHS-114	Merus N.V. (MRUS)
day301	Day One Biopharmaceuticals, Inc. (DAWN)
EO-3021	Elevation Oncology, Inc. (ELEV)
ERAS-0015	Erasca, Inc. (ERAS)
ERAS-0015 in combination	Erasca, Inc. (ERAS)
ERAS-007	Erasca, Inc. (ERAS)
ERAS-12	Erasca, Inc. (ERAS)
ERAS-3490	Erasca, Inc. (ERAS)
ERAS-4	Erasca, Inc. (ERAS)
ERAS-4001	Erasca, Inc. (ERAS)
ERAS-4001 in combination	Erasca, Inc. (ERAS)
ERAS-601	Erasca, Inc. (ERAS)
etigilimab	OncoMed Pharmaceuticals Inc (OMED)
hro761	Novartis AG (NVS)
hro761	NOVARTIS AG (NVSEF)
IDE-161	IDEAYA Biosciences, Inc. (IDYA)
kzr-261	Kezar Life Sciences, Inc. (KZR)
LY4050784	ELI LILLY & Co (LLY)
ly4052031	ELI LILLY & Co (LLY)
LY4101174	ELI LILLY & Co (LLY)
MRG007	ArriVent BioPharma, Inc. (AVBP)
Naporafenib	Erasca, Inc. (ERAS)
ngm438	NGM BIOPHARMACEUTICALS INC (NGM)
ngm831	NGM BIOPHARMACEUTICALS INC (NGM)
ST101	Janux Therapeutics, Inc. (JANX)
ST101	Merus N.V. (MRUS)
ST101	PTC THERAPEUTICS, INC. (PTCT)
ST101	Myovant Sciences Ltd. (MYOV)
ST101	Royalty Pharma plc (RPRX)
TAK-188	Merus N.V. (MRUS)
Temozolomide	Myovant Sciences Ltd. (MYOV)
Temozolomide	Royalty Pharma plc (RPRX)
Temozolomide	Janux Therapeutics, Inc. (JANX)
Trametinib	Erasca, Inc. (ERAS)
wtx-124	Werewolf Therapeutics, Inc. (HOWL)
XB010	EXELIXIS, INC. (EXEL)

Preclinical(4)

Drug	Company
BP1003	BIO-PATH HOLDINGS, INC. (BPTH)
ck-103	Checkpoint Therapeutics, Inc. (CKPT)
CLD-400 (RTNova)	Calidi Biotherapeutics Inc. (CLDI)
iv rhdnase i	Xenetic Biosciences, Inc. (XBIO)

BLA Filed(1)

Drug	Company
larotrectinib	LOXO ONCOLOGY, INC. (LOXO)

Phase 1/Phase 2(9)

Drug	Company
cr-001	CRESCENT BIOPHARMA, INC. (CBIO)
dcc-3116	Deciphera Pharmaceuticals, Inc. (DCPH)
iph4502	Innate Pharma SA (IPHYF)
mrtx1719	Mirati Therapeutics, Inc. (MRTX)
nc762	NextCure, Inc. (NXTC)
surufatinib and tislelizumab _ part 1	HUTCHMED (China) Limited (HCM)
surufatinib and tislelizumab _ part 2	HUTCHMED (China) Limited (HCM)
tislelizumab	HUTCHMED (China) Limited (HCM)
wtx-330	Werewolf Therapeutics, Inc. (HOWL)

Phase 2/Phase 3(2)

Drug	Company
surufatinib	HUTCHMED (China) Limited (HCM)
surufatinib combined with camrelizumab	HUTCHMED (China) Limited (HCM)

Phase 4(2)

Drug	Company
saruparib	ASTRAZENECA PLC (AZN)
toripalimab	Coherus Oncology, Inc. (CHRS)

BioSniper tracks 79 drugs in development for Metastatic Solid Tumor across 42 companies.

There are 29 clinical trials targeting Metastatic Solid Tumor tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.